Objective To observe the clinical curative effect of Wumei Pill in the treatment of cold-heat complex diarrhea-predominant irritable bowel syndrome.Methods Modified Wumei Pill was adopted to treat 46 cases of cold-heat complex diarrhea predominant irritable bowel syndrome.Five main symptoms of stool frequency,stool shape and properties,abdominal pain and discomfort,bowel gurgling,vulnerable to the cold were observed.The symptom scores before the treatment and 1 week,2 weeks and 4 weeks after the treatment were evaluated.Results After the treatment of 1 week,2 weeks and 4 weeks,the overall efficiency was 58.70％(27/46),84.78％(39/46),and 97.83％(45/46) respectively,and there were significant differences in curative effect between the different treatment courses (between treatment of 2 weeks and 1 weekx2＝8.571,between treatment of 4 weeks and 2 weekx2=16.426,between treatment of 4 weeks and 1 week x2=35.622).Effective rate of symptoms after 4 weeks treatment were respectively:stool frequency 82.05％ (32/39),stool shape and properties 95.56％ (43/45),abdominal pain and discomfort 92.86％ (39/42),bowel gurgling 85.71％ (18/21),vulnerable to the cold 64.29％ (27/42),and there was obvious differences in effective percentage of five kinds of symptoms between treatment of 4 weeks and 1 week (Stool frequency x2 =7.123、stool shape and properties x2 =13.611、abdominal pain or discomfort x2 =7.721、bowel gurgling x2=10.096、vulnerable to the cold x2=10.769).Conclusion.The clinical effect of Wumei Pill for the treatment of cold-heat complex diarrhea predominant irritable bowel syndrome was defined.

Objective To discuss the developing law of pathogeny and mechanism of chronic hepatitis type B.Methods Patients of chronic hepatitis type B,early hepatocirrhosis and ascites caused by hepatocirrhosis was chosen as objects and clinical information was collected face to face.Patterns of Chinese medicine were confirmed and counted seperately according to efficiency,deficiency and efficiency-deficiency sydrome,harmed Zang-Fu organs and syndrome factors.Finally,the developing law of pathogeny and mechanism was analyzed.Results As the state of chronic hepatitis type Bevolving,simple efficiency and deficiency sydrome decrease with efficiency-deficiency sydrome increasing.Zang-Fu organs damaged by chronic hepatitis type B including mostly liver,gallblader,spleen,stomach,kidney,Trijiao and so on,among which spleen and liver are mainly damaged.As the state of chronic hepatitis type B evolving,the frequencies of damage to gallblader,spleen,stomach,kidney,Trijiao and so on increase.Most simple chronic hepatitis type B cases are due to Shi,Shi-Re,efficiency and stasis of Qi,while most of early hepatocirrhosis stem from Shi-Re,extravasated blood,efficiency and stasis of Qi,with that of ascites caused by hepatocirrhosis originating from Shi-Re,extravasated blood,Shui,efficiency of Qi and Yin. Conclusion There is developing law in the character,location and syndrome factors of chronic hepatitis type B.

Objective To observe the effects of Qishu granule on PI3K/Akt signaling transduction pathways in the process of hepatic fibrosis, and further explain the anti-hepatic fibrosis mechanism of Qishu granule.Methods Wistar rats were randomly divided into normal group, model group, experimental control group and Qishu granule group. Liver fibrosis was duplicated in rats by intraperitoneal injection of CCl4, and the rats were given appropriate treatment at the same day. Rats in Qishu granule group were given a gavage 2 g/(kg?d), 1.0 mL/100 g, while rats in experimental control group and normal group were given the same amount of aquae sterilisata. Rats in each group were taken liver tissue samples in the 1st, 2nd and 4th week, and were checked for the protein expression levels of p-Akt (Ser473), p-Akt (Thr308), Bad (Ser136) and Caspase9 by Western blot.Results Compared with the model group, expression levels of p-Akt (Ser473), p-Akt (Thr308), Bad (Ser136) and Caspase9 in model and Qishu granule groups increased in every time points (P<0.05). Compared with the model group, expression level of p-Akt (Ser473) in Qishu granule group decreased significantly in the 1st, 2nd, and 4th weeks, expression level of Caspase9 dropped in the 1st and the 4th weeks, with statistical significance (P<0.05,P<0.01);expressions of p-Akt (Thr308) and Bad (Ser136) were lower than those in model group, without statistical significance (P>0.05).Conclusion Qishu granule could regulate PI3K/Akt signaling transduction pathways, and inhibit the occurrence and development of liver fibrosis.

ObjectiveTo investigate the clinical efficacy of Zisheng pills in the treatment of adverse reactions in patients with primary hepatocellular carcinoma (HCC) after transcatheter arterial chemoembolization (TACE). MethodsThis study included 72 patients with liver cancer hospitalized in the Department of Liver Diseases and Department of Oncology, Wenzhou Hospital of Traditional Chinese Medicine, from June 2011 to May 2014. These cases were randomly divided into treatment group (n=37) and control group (n=35). All the patients were treated with TACE, as well as conventional symptomatic and supportive treatment. In addition, the treatment group was given Zisheng pills (one bag) three times a day for at least three consecutive months. Comparison of categorical data was made by chi-square test, while comparison of continuous data (expressed as mean±SD) was made by t test. Survival comparison was made by Kaplan-Meier method and log-rank test. ResultsAfter the first TACE, there were significant differences in poor appetite and abdominal distension between the treatment group and the control group (P＜0.05); significant differences were also observed in CD3+ and CD4+ T lymphocytes between the two groups (P＜0.05). After the second TACE, there were significant differences in postoperative fatigue, poor appetite, and abdominal distension, as well as postoperative Karnofsky score, between the treatment group and the control group (P＜0.05); significant differences were also found in CD3+, CD4+, and CD8+ T lymphocytes and CD4+/CD8+ ratio between the two groups (P＜0.05). The median survival time showed no significant differences between the treatment group and the control group (82 vs 74 weeks, P＞0.05), but the 2-year overall survival rate was significantly higher in the treatment group than in the control group (43.2% vs 20%, P＜0.05). ConclusionZisheng pills have good clinical efficacy in the treatment of adverse reactions in liver cancer patients after TACE, and it can improve the symptoms and quality of life, regulate peripheral blood T lymphocyte subsets, and increase the 2-year overall survival rate.